Human CXCL13/BLC/BCA-1 Antibody

Catalog # Availability Size / Price Qty
Chemotaxis Induced by CXCL13/BLC/BCA‑1 and Neutralization by Human CXCL13/BLC/BCA‑1 Antibody.
2 Images
Product Details
Citations (18)
Supplemental Products

Human CXCL13/BLC/BCA-1 Antibody Summary

Species Reactivity
Detects CXCL13/BLC/BCA‑1 in direct ELISAs and Western blots. 
Polyclonal Goat IgG
Antigen Affinity-purified
E. coli-derived recombinant human CXCL13/BCA-1
Accession # Q53X90
Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
Endotoxin Level
<0.10 EU per 1 μg of the antibody by the LAL method.


Recommended Concentration
Western Blot
0.1 µg/mL
Recombinant Human CXCL13/BLC/BCA‑1 (Catalog # 801-CX)
5-15 µg/mL
See below
Measured by its ability to neutralize CXCL13/BLC/BCA‑1-induced chemotaxis in the BaF3 mouse pro‑B cell line transfected with human CXCR5. The Neutralization Dose (ND50) is typically 1-4 µg/mL in the presence of 50 ng/mL Recombinant Human CXCL13/BLC/BCA‑1.

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

Scientific Data

Neutralization Chemotaxis Induced by CXCL13/BLC/BCA‑1 and Neutralization by Human CXCL13/BLC/BCA‑1 Antibody. View Larger

Chemotaxis Induced by CXCL13/BLC/BCA‑1 and Neutralization by Human CXCL13/BLC/BCA‑1 Antibody. Recombinant Human CXCL13/BLC/BCA-1 (Catalog # 801-CX) chemoattracts the BaF3 mouse pro-B cell line transfected with human CXCR5 in a dose-dependent manner (orange line). The amount of cells that migrated through to the lower chemotaxis chamber was measured by Resazurin. Chemotaxis elicited by Recombinant Human CXCL13/BLC/BCA-1 (50 ng/mL) is neutralized (green line) by increasing concentrations of Goat Anti-Human CXCL13/BLC/BCA-1 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF801). The ND50 is typically 1-4 µg/mL.

Immunohistochemistry CXCL13/BLC/BCA-1 antibody in Human Lymphoma by Immunohistochemistry (IHC-P). View Larger

CXCL13/BLC/BCA‑1 in Human Lymphoma. CXCL13/BLC/BCA-1 was detected in immersion fixed paraffin-embedded sections of human lymphoma using Goat Anti-Human CXCL13/BLC/BCA-1 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF801) at 10 µg/mL overnight at 4 °C. Before incubation with the primary antibody, tissue was subjected to heat-induced epitope retrieval using Antigen Retrieval Reagent-Basic (Catalog # CTS013). Tissue was stained using the Anti-Goat HRP-DAB Cell & Tissue Staining Kit (brown; Catalog # CTS008) and counterstained with hematoxylin (blue). Specific staining was localized to cytoplasm. View our protocol for Chromogenic IHC Staining of Paraffin-embedded Tissue Sections.

Reconstitution Calculator

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Preparation and Storage

Reconstitute at 0.2 mg/mL in sterile PBS.
Reconstitution Buffer Available
Reconstitution Buffer 1 (PBS)
Catalog #
Size / Price
The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C
Stability & Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: CXCL13/BLC/BCA-1

CXCL13, also known as B-lymphocyte chemoattractant (BLC), is a CXC chemokine that is constitutively expressed in secondary lymphoid organs. BCA-1 cDNA encodes a protein of 109 amino acid residues with a leader sequence of 22 residues. Mature human BCA-1 shares 64% amino acid sequence similarity with the mouse protein and 23‑34% amino acid sequence identity with other known CXC chemokines. Recombinant or chemically synthesized BCA-1 is a potent chemoattractant for B lymphocytes but not T lymphocytes, monocytes or neutrophils. BLR1, a G protein-coupled receptor originally isolated from Burkitt’s lymphoma cells, has now been shown to be the specific receptor for BCA1. Among cells of the hematopoietic lineages, the expression of BLR1, now designated CXCR5, is restricted to B lymphocytes and a subpopulation of T helper memory cells. Mice lacking BLR1 have been shown to lack inguinal lymph nodes. These mice were also found to have impaired development of Peyer’s patches and defective formation of primary follicles and germinal centers in the spleen as a result of the inability of B lymphocytes to migrate into B cell areas.

  1. Gunn, M.D. et al. (1998) Nature, 391:799.
  2. Legler, D.F. et al. (1998) J. Exp. Med. 187:655.
  3. Forster, R. et al. (1996) Cell 87:1037.
Entrez Gene IDs
10563 (Human); 55985 (Mouse)
Alternate Names
ANGIE; ANGIE2; B cell-attracting chemokine 1; B lymphocyte chemoattractant; BCA1; BCA-1; BCA1B-cell chemoattractant; BCA-1CXC chemokine BLC; B-cell-homing chemokine (ligand for Burkitt's lymphoma receptor-1); BLC; BLCSmall-inducible cytokine B13; BLR1L; B-lymphocyte chemoattractant; chemokine (C-X-C motif) ligand 13 (B-cell chemoattractant); chemokine (C-X-C motif) ligand 13; C-X-C motif chemokine 13; CXCL13; SCYB13; SCYB13B-cell-attracting chemokine 1; small inducible cytokine B subfamily (Cys-X-Cys motif), member 13 (B-cellchemoattractant)

Product Datasheets

You must select a language.


Citations for Human CXCL13/BLC/BCA-1 Antibody

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

18 Citations: Showing 1 - 10
Filter your results:

Filter by:

  1. CXCL13 is a predictive biomarker in idiopathic multicentric Castleman disease
    Authors: SK Pierson, L Katz, R Williams, M Mumau, M Gonzalez, S Guzman, A Rubenstein, AB Oromendia, P Beineke, A Fosså, F van Rhee, DC Fajgenbaum
    Nature Communications, 2022;13(1):7236.
    Species: Human
    Sample Types: Whole Tissue
    Applications: IHC
  2. Ulcerative colitis is characterized by a plasmablast-skewed humoral response associated with disease activity
    Authors: M Uzzan, JC Martin, L Mesin, AE Livanos, T Castro-Dop, R Huang, F Petralia, G Magri, S Kumar, Q Zhao, AK Rosenstein, M Tokuyama, K Sharma, R Ungaro, R Kosoy, D Jha, J Fischer, H Singh, ME Keir, N Ramamoorth, WEO Gorman, BL Cohen, A Rahman, F Cossarini, A Seki, L Leyre, ST Vaquero, S Gurunathan, EK Grasset, B Losic, M Dubinsky, AJ Greenstein, Z Gottlieb, P Legnani, J George, H Irizar, A Stojmirovi, C Brodmerkel, A Kasarkis, BE Sands, G Furtado, SA Lira, ZK Tuong, HM Ko, A Cerutti, CO Elson, MR Clatworthy, M Merad, M Suárez-Far, C Argmann, JA Hackney, GD Victora, GJ Randolph, E Kenigsberg, JF Colombel, S Mehandru
    Nature Medicine, 2022;0(0):.
    Species: Human
    Sample Types: Whole Tissue
    Applications: IHC
  3. Defined tumor antigen-specific T cells potentiate personalized TCR-T cell therapy and prediction of immunotherapy response
    Authors: J He, X Xiong, H Yang, D Li, X Liu, S Li, S Liao, S Chen, X Wen, K Yu, L Fu, X Dong, K Zhu, X Xia, T Kang, C Bian, X Li, H Liu, P Ding, X Zhang, Z Liu, W Li, Z Zuo, P Zhou
    Cell Research, 2022;0(0):.
    Species: Xenograft
    Sample Types: Whole Tissue
    Applications: IHC
  4. Immune cell topography predicts response to PD-1 blockade in cutaneous T cell lymphoma
    Authors: D Phillips, M Matusiak, BR Gutierrez, SS Bhate, GL Barlow, S Jiang, J Demeter, KS Smythe, RH Pierce, SP Fling, N Ramchurren, MA Cheever, Y Goltsev, RB West, MS Khodadoust, YH Kim, CM Schürch, GP Nolan
    Nature Communications, 2021;12(1):6726.
    Species: Human
    Sample Types: Whole Tissue
    Applications: IHC
  5. Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial
    Authors: N van Dijk, A Gil-Jimene, K Silina, K Hendrickse, LA Smit, JM de Feijter, ML van Montfo, C van Rooije, D Peters, A Broeks, HG van der Po, A Bruining, Y Lubeck, K Sikorska, TN Boellaard, P Kvistborg, DJ Vis, E Hooijberg, TN Schumacher, M van den Br, LFA Wessels, CU Blank, BW van Rhijn, MS van der He
    Nat Med, 2020;0(0):.
    Species: Human
    Sample Types: Whole Tissue
    Applications: IHC
  6. Histopathology and expression of the chemokines CXCL10, CXCL13, and CXCR3 and the endogenous TLR-4 ligand S100A8/A9 in lymph nodes of patients with adult-onset Still's disease
    Authors: HA Kim, YH Kim, YK Jeon, WI Yang, JE Kwon, JH Han
    Sci Rep, 2019;9(1):7517.
    Species: Human
    Sample Types: Whole Tissue
    Applications: IHC-P
  7. Elevated Expression of Chemokine CXCL13 in Chronic Hepatitis B Patients Links to Immune Control during Antiviral Therapy
    Authors: C Liu, X Huang, M Werner, R Broering, J Ge, Y Li, B Liao, J Sun, J Peng, M Lu, J Hou, X Zhang
    Front Immunol, 2017;8(0):323.
    Species: Human
    Sample Types: Whole Tissue
    Applications: IHC
  8. Hif1a Deletion Reveals Pro-Neoplastic Function of B Cells in Pancreatic Neoplasia
    Cancer Discov, 2016;6(3):256-69.
    Species: Human
    Sample Types: Whole Tissue
    Applications: IHC-P
  9. Control of the T follicular helper-germinal center B-cell axis by CD8(+) regulatory T cells limits atherosclerosis and tertiary lymphoid organ development.
    Authors: Clement M, Guedj K, Andreata F, Morvan M, Bey L, Khallou-Laschet J, Gaston A, Delbosc S, Alsac J, Bruneval P, Deschildre C, Le Borgne M, Castier Y, Kim H, Cantor H, Michel J, Caligiuri G, Nicoletti A
    Circulation, 2015;131(6):560-70.
    Species: Human
    Sample Types: Whole Tissue
    Applications: IHC-P
  10. Occurrence of tertiary lymphoid tissue is associated with T-cell infiltration and predicts better prognosis in early-stage colorectal cancers.
    Authors: Di Caro G, Bergomas F, Grizzi F, Doni A, Bianchi P, Malesci A, Laghi L, Allavena P, Mantovani A, Marchesi F
    Clin Cancer Res, 2014;20(8):2147-58.
    Species: Human
    Sample Types: Whole Tissue
    Applications: IHC-P
  11. CXCR5(+) T helper cells mediate protective immunity against tuberculosis.
    Authors: Slight S, Rangel-Moreno J, Gopal R, Lin Y, Fallert Junecko B, Mehra S, Selman M, Becerril-Villanueva E, Baquera-Heredia J, Pavon L, Kaushal D, Reinhart T, Randall T, Khader S
    J Clin Invest, 2013;123(2):712-26.
    Species: Human
    Sample Types: Whole Tissue
    Applications: IHC-P
  12. Thymic alterations in GM2 gangliosidoses model mice.
    Authors: Kanzaki S, Yamaguchi A, Yamaguchi K, Kojima Y, Suzuki K, Koumitsu N, Nagashima Y, Nagahama K, Ehara M, Hirayasu Y, Ryo A, Aoki I, Yamanaka S
    PLoS ONE, 2010;5(8):.
    Species: Mouse
    Sample Types: Whole Tissue
    Applications: IHC-Fr
  13. Mature antigen-experienced T helper cells synthesize and secrete the B cell chemoattractant CXCL13 in the inflammatory environment of the rheumatoid joint.
    Arthritis Rheum., 2008;58(0):3377-87.
    Species: Human
    Sample Types: Whole Cells
    Applications: ICC
  14. Interaction of the Lyme disease spirochete Borrelia burgdorferi with brain parenchyma elicits inflammatory mediators from glial cells as well as glial and neuronal apoptosis.
    Authors: Ramesh G, Borda JT, Dufour J, Kaushal D, Ramamoorthy R, Lackner AA, Philipp MT
    Am. J. Pathol., 2008;173(5):1415-27.
    Species: Primate - Macaca mulatta (Rhesus Macaque)
    Sample Types: Whole Tissue
    Applications: IHC-Fr
  15. Increased serum levels of the chemokine CXCL13 and up-regulation of its gene expression are distinctive features of HCV-related cryoglobulinemia and correlate with active cutaneous vasculitis.
    Authors: Sansonno D, Tucci FA, Troiani L, Lauletta G, Montrone M, Conteduca V, Sansonno L, Dammacco F
    Blood, 2008;112(5):1620-7.
    Species: Human
    Sample Types: Whole Tissue
    Applications: IHC-P
  16. Recapitulation of B cell differentiation in the central nervous system of patients with multiple sclerosis.
    Authors: Casazza S, Zappia E, Pistorio A, Gambini C
    Proc. Natl. Acad. Sci. U.S.A., 2004;101(30):11064-9.
    Species: Human
    Sample Types: Whole Tissue
    Applications: IHC-P
  17. Developing neonatal rabbit appendix, a primary lymphoid organ, is seeded by immature blood-borne B cells: evidence for roles for CD62L/PNAd, CCR7/CCL21, alpha4beta1 and LFA-1.
    Authors: Sinha RK, Mage RG
    Dev. Comp. Immunol., 2004;28(7):829-41.
    Species: Rabbit
    Sample Types: Whole Tissue
    Applications: IHC
  18. Classification of distinct subtypes of peripheral T-cell lymphoma unspecified, identified by chemokine and chemokine receptor expression: Analysis of prognosis.
    Authors: Ohshima K, Karube K, Kawano R, Tsuchiya T, Suefuji H, Yamaguchi T, Suzumiya J, Kikuchii M
    Int. J. Oncol., 2004;25(3):605-13.
    Species: Human
    Sample Types: Whole Tissue
    Applications: IHC-P


No product specific FAQs exist for this product, however you may

View all Antibody FAQs

Isotype Controls

Reconstitution Buffers

Secondary Antibodies

Reviews for Human CXCL13/BLC/BCA-1 Antibody

There are currently no reviews for this product. Be the first to review Human CXCL13/BLC/BCA-1 Antibody and earn rewards!

Have you used Human CXCL13/BLC/BCA-1 Antibody?

Submit a review and receive an Amazon gift card.

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review